Cargando…

Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer

Purpose: The clinical significance of preoperative serum levels of carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) in breast cancer is controversial. The purpose of this study was to assess the clinical value of preoperative serum levels of CEA and CA 15-3 on the risk of axillary lym...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, San-Gang, He, Zhen-Yu, Ren, Hong-Yue, Yang, Li-Chao, Sun, Jia-Yuan, Li, Feng-Yan, Guo, Ling, Lin, Huan-Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679379/
https://www.ncbi.nlm.nih.gov/pubmed/26722358
http://dx.doi.org/10.7150/jca.13090
_version_ 1782405571007217664
author Wu, San-Gang
He, Zhen-Yu
Ren, Hong-Yue
Yang, Li-Chao
Sun, Jia-Yuan
Li, Feng-Yan
Guo, Ling
Lin, Huan-Xin
author_facet Wu, San-Gang
He, Zhen-Yu
Ren, Hong-Yue
Yang, Li-Chao
Sun, Jia-Yuan
Li, Feng-Yan
Guo, Ling
Lin, Huan-Xin
author_sort Wu, San-Gang
collection PubMed
description Purpose: The clinical significance of preoperative serum levels of carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) in breast cancer is controversial. The purpose of this study was to assess the clinical value of preoperative serum levels of CEA and CA 15-3 on the risk of axillary lymph node metastasis (ALNM) in patients with breast cancer. Methods: This retrospective study analyzed 1148 breast cancer patients whose preoperative CEA and CA 15-3 levels were measured. The association of these tumor markers and clinicopathologic parameters with ALNM was determined by univariate and multivariate analysis. Results: A median of 15 lymph nodes were removed. Seven hundred seventy-eight (67.8%) patients had node-negative disease and 370 (32.2%) had ALNM. Univariate analysis showed that tumor location (P = 0.024), stage (P = 0.001), grade (P < 0.001), lymphovascular invasion (LVI) (P < 0.001), CEA level (P < 0.001), CA15-3 level (P < 0.001), and breast cancer subtype (BCS) (P < 0.001) were significantly associated with ALNM. ALNM was present in 4.5% of patients with normal CEA and 11.6% of patients with elevated CEA. ALNM was present in 8.0% of patients with normal CA15-3 and 17.0% of patients with high CA15-3. Multivariate logistic regression analysis showed that tumor location, stage, grade, LVI, CEA, CA15-3, and BCS were significantly and independently associated with ALNM (P < 0.05 for all). Conclusion: The probability of ALNM was greater in patients with elevated preoperative serum levels of CEA and CA15-3. CEA and CA15-3 appear to be independent predictors of ALNM in breast cancer.
format Online
Article
Text
id pubmed-4679379
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-46793792016-01-01 Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer Wu, San-Gang He, Zhen-Yu Ren, Hong-Yue Yang, Li-Chao Sun, Jia-Yuan Li, Feng-Yan Guo, Ling Lin, Huan-Xin J Cancer Research Paper Purpose: The clinical significance of preoperative serum levels of carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) in breast cancer is controversial. The purpose of this study was to assess the clinical value of preoperative serum levels of CEA and CA 15-3 on the risk of axillary lymph node metastasis (ALNM) in patients with breast cancer. Methods: This retrospective study analyzed 1148 breast cancer patients whose preoperative CEA and CA 15-3 levels were measured. The association of these tumor markers and clinicopathologic parameters with ALNM was determined by univariate and multivariate analysis. Results: A median of 15 lymph nodes were removed. Seven hundred seventy-eight (67.8%) patients had node-negative disease and 370 (32.2%) had ALNM. Univariate analysis showed that tumor location (P = 0.024), stage (P = 0.001), grade (P < 0.001), lymphovascular invasion (LVI) (P < 0.001), CEA level (P < 0.001), CA15-3 level (P < 0.001), and breast cancer subtype (BCS) (P < 0.001) were significantly associated with ALNM. ALNM was present in 4.5% of patients with normal CEA and 11.6% of patients with elevated CEA. ALNM was present in 8.0% of patients with normal CA15-3 and 17.0% of patients with high CA15-3. Multivariate logistic regression analysis showed that tumor location, stage, grade, LVI, CEA, CA15-3, and BCS were significantly and independently associated with ALNM (P < 0.05 for all). Conclusion: The probability of ALNM was greater in patients with elevated preoperative serum levels of CEA and CA15-3. CEA and CA15-3 appear to be independent predictors of ALNM in breast cancer. Ivyspring International Publisher 2016-01-01 /pmc/articles/PMC4679379/ /pubmed/26722358 http://dx.doi.org/10.7150/jca.13090 Text en © Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions.
spellingShingle Research Paper
Wu, San-Gang
He, Zhen-Yu
Ren, Hong-Yue
Yang, Li-Chao
Sun, Jia-Yuan
Li, Feng-Yan
Guo, Ling
Lin, Huan-Xin
Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer
title Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer
title_full Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer
title_fullStr Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer
title_full_unstemmed Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer
title_short Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer
title_sort use of cea and ca15-3 to predict axillary lymph node metastasis in patients with breast cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679379/
https://www.ncbi.nlm.nih.gov/pubmed/26722358
http://dx.doi.org/10.7150/jca.13090
work_keys_str_mv AT wusangang useofceaandca153topredictaxillarylymphnodemetastasisinpatientswithbreastcancer
AT hezhenyu useofceaandca153topredictaxillarylymphnodemetastasisinpatientswithbreastcancer
AT renhongyue useofceaandca153topredictaxillarylymphnodemetastasisinpatientswithbreastcancer
AT yanglichao useofceaandca153topredictaxillarylymphnodemetastasisinpatientswithbreastcancer
AT sunjiayuan useofceaandca153topredictaxillarylymphnodemetastasisinpatientswithbreastcancer
AT lifengyan useofceaandca153topredictaxillarylymphnodemetastasisinpatientswithbreastcancer
AT guoling useofceaandca153topredictaxillarylymphnodemetastasisinpatientswithbreastcancer
AT linhuanxin useofceaandca153topredictaxillarylymphnodemetastasisinpatientswithbreastcancer